Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1978 Aug;38(2):237–249. doi: 10.1038/bjc.1978.194

Thyroid tumours in rats and hepatomas in mice after griseofulvin treatment.

M Rustia, P Shubik
PMCID: PMC2009728  PMID: 698038

Abstract

Griseofulvin, an antibiotic used to treat dermatophystosis, was tested for carcinogenicity in mice, rats and hamsters. Three groups of mice and rats were given the drug in powdered diet in alternating 5-week periods for life, at dose levels of 3.0%, 1.5% and 0.3% (mice) and 2.0%, 1.0% and 0.2% (rats). A group of mice and 3 groups of hamsters received continuous daily treatment for life with griseofulvin at 3.0%, 1.5%, 0.3% and 0.1% dose levels respectively. A significant incidence of hepatic tumours was observed at the 2 higher treatment levels in mice. Also, statistically significant rates (P less than or equal to 0.001 and/or P less than or equal to 0.020) of thyroid tumours, indicating a dose-response, were recorded in male rats at the 2.0%, 1.0%, and 0.2% dose levels, and in females at the 2.0% and 1.0% dose levels. Hamsters did not develop neoplasms in response to treatment at any level.

Full text

PDF
237

Images in this article

242Figs. 2-5
on p.242
245Figs. 6-9
on p.245

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANDERSON D. W. GRISEOFULVIN: BIOLOGY AND CLINICAL USEFULNESS. A REVIEW. Ann Allergy. 1965 Feb;23:103–110. [PubMed] [Google Scholar]
  2. BARICH L. L., NAKAI T., SCHWARZ J., BARICH D. J. Tumour-promoting effect of excessively large doses of oral griseofulvin on tumours induced in mice by methylcholanthrene. Nature. 1960 Jul 23;187:335–336. doi: 10.1038/187335b0. [DOI] [PubMed] [Google Scholar]
  3. BARICH L. L., SCHWARZ J., BARICH D. Oral griseofulvin: a cocarcinogenic agent to methylcholanthrene induced cutaneous tumors. Cancer Res. 1962 Jan;22:53–55. [PubMed] [Google Scholar]
  4. BLANK H., SMITH J. G., Jr, ROTH F. J., Jr, ZAIAS N. Griseofulvin for the systemic treatment of dermatomycoses. J Am Med Assoc. 1959 Dec 19;171:2168–2173. doi: 10.1001/jama.1959.03010340012003. [DOI] [PubMed] [Google Scholar]
  5. DE MATTEIS F., RIMINGTON C. Disturbance of porphyrin metabolism caused by griseofulvin in mice. Br J Dermatol. 1963 Mar;75:91–104. doi: 10.1111/j.1365-2133.1963.tb13945.x. [DOI] [PubMed] [Google Scholar]
  6. EPSTEIN W. L., LARSON M. A. Griseofulvin potentiation of colchicine toxicity. J Invest Dermatol. 1961 Jan;36:5–6. [PubMed] [Google Scholar]
  7. Epstein S. S., Andrea J., Joshi S., Mantel N. Hepatocarcinogenicity of griseofulvin following parenteral administration to infant mice. Cancer Res. 1967 Oct;27(10):1900–1906. [PubMed] [Google Scholar]
  8. Grasso P., Crampton R. F. The value of the mouse in carcinogenicity testing. Food Cosmet Toxicol. 1972 Jun;10(3):418–426. [PubMed] [Google Scholar]
  9. Grin E. I. A controlled trial of home versus hospital treatment of tinea capitis with griseofulvin. Bull World Health Organ. 1965;33(2):193–196. [PMC free article] [PubMed] [Google Scholar]
  10. Klein M. F., Beall J. R. Griseofulvin: a teratogenic study. Science. 1972 Mar 31;175(4029):1483–1484. doi: 10.1126/science.175.4029.1483. [DOI] [PubMed] [Google Scholar]
  11. LINDSAY S., SHELINE G. E., POTTER G. D., CHAIKOFF I. L. Induction of neoplasms in the thyroid gland of the rat by x-irradiation of the gland. Cancer Res. 1961 Jan;21:9–16. [PubMed] [Google Scholar]
  12. Lindsay S., Nichols C. W., Jr, Chaikoff I. L. Carcinogenic effect of irradiation. Low doses of radioactive iodine on the thyroid gland of the rat and mouse. Arch Pathol. 1968 May;85(5):487–492. [PubMed] [Google Scholar]
  13. Lochhead A. C., Dagg J. H., Goldberg A. Experimental griseofulvin porphyria in adult and foetal mice. Br J Dermatol. 1967 Feb;79(2):96–102. doi: 10.1111/j.1365-2133.1967.tb11463.x. [DOI] [PubMed] [Google Scholar]
  14. MONEY W. L., TYPOND P., RAWSON R. W. THE GROWTH AND FUNCTION OF THIOURACIL-INDUCED THYROID TUMORS TRANSPLANTED INTO NON-INBRED RATS THYMECTOMIZED AT BIRTH. Cancer Res. 1965 May;25:423–431. [PubMed] [Google Scholar]
  15. NICHOLS C. W., Jr, LINDSAY S., SHELINE G. E., CHAIKOFF I. L. INDUCTION OF NEOPLASMS IN RAT THYROID GLANDS BY X-IRRADIATION OF A SINGLE LOBE. Arch Pathol. 1965 Aug;80:177–183. [PubMed] [Google Scholar]
  16. Oxford A. E., Raistrick H., Simonart P. Studies in the biochemistry of micro-organisms: Griseofulvin, C(17)H(17)O(6)Cl, a metabolic product of Penicillium griseo-fulvum Dierckx. Biochem J. 1939 Feb;33(2):240–248. doi: 10.1042/bj0330240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. PAGET G. E., ALCOCK S. J. Griseofulvin and colchicine: lack of carcinogenic action. Nature. 1960 Dec 3;188:867–867. doi: 10.1038/188867a0. [DOI] [PubMed] [Google Scholar]
  18. PAGET G. E., WALPOLE A. L. Some cytological effects of griseofulvin. Nature. 1958 Nov 8;182(4645):1320–1321. doi: 10.1038/1821320a0. [DOI] [PubMed] [Google Scholar]
  19. REDEKER A. G., STERLING R. E., BRONOW R. S. EFFECT OF GRISEOFLUVIN IN ACUTE INTERMITTENT PORPHYRIA. JAMA. 1964 May 4;188:466–468. doi: 10.1001/jama.1964.03060310066017. [DOI] [PubMed] [Google Scholar]
  20. RIMINGTON C., MORGAN P. N., NICHOLLS K., EVERALL J. D., DAVIES R. R. GRISEOFULVIN ADMINISTRATION AND PORPHYRIN METABOLISM. A SURVEY. Lancet. 1963 Aug 17;2(7303):318–322. doi: 10.1016/s0140-6736(63)92989-1. [DOI] [PubMed] [Google Scholar]
  21. Scott F. W., LaHunta A., Schultz R. D., Bistner S. I., Riis R. C. Teratogenesis in cats associated with griseofulvin therapy. Teratology. 1975 Feb;11(1):79–86. doi: 10.1002/tera.1420110110. [DOI] [PubMed] [Google Scholar]
  22. Tomatis L., Partensky C., Montesano R. The predictive value of mouse liver tumour induction in carcinogenicity testing--a literature survey. Int J Cancer. 1973 Jul 15;12(1):1–20. doi: 10.1002/ijc.2910120102. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES